# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces ...
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses o...
- SEC Filing
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...
Key Takeaways: Akeso swung to an annual profit of 1.94 billion yuan, boosted by licensing income of 2.92 billion yuan The n...
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expan...
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Stifel analyst Brad Canino initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Tar...